| | CEOP/IVE/GDP (N = 51) * | CEOP (N = 51) * | p value |
|---|
| Response at interim |
| Complete response | 17 (33.3%) | 18 (35.3%) | 0.834 |
| Partial response | 26 (51.0%) | 13 (25.5%) | 0.008 |
| Stable disease | 4 (7.8%) | 7 (13.7%) | |
| Disease progression | 3 (5.9%) | 11 (21.6%) | |
| Overall response | 43 (84.3%) | 31 (60.8%) | 0.008 |
| Response at EOT |
| Complete response | 19 (37.3%) | 16 (31.4%) | 0.532 |
| Partial response | 18 (35.3%) | 9 (17.6%) | 0.042 |
| Stable disease | 4 (7.8%) | 7 (13.7%) | |
| Disease progression | 9 (17.6%) | 17 (33.3%) | |
| Overall response | 37 (72.5%) | 25 (49. 0%) | 0.015 |
- EOT end of treatment
- *One patient in the CEOP/IVE/GDP group could not be evaluated due to toxicity (n = 1). Two patients in the CEOP group could not be evaluated due to toxicity (n = 1) and consent withdrawal (n = 1). All the three patients were considered as no responders from statistically conservative consideration
